Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

FONTAN

Showing results (551-560 of 568) with videos related to

Pageof 57
Sort By:
Plos One|February 19, 2021
Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 RegistryJesús Díez-Manglano, Marta Nataya Solís-Marquínez, Andrea Álvarez García, et al.
Haematologica|September 2, 2018
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphomaRémy Gressin, Nicolas Daguindau, Adrian Tempescul, et al.
Plos One|May 11, 2021
Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVIDJorge Calderón-Parra, Antonio Muiño-Miguez, Alejandro D Bendala-Estrada, et al.
Blood|September 24, 2025
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Aurore Perrot, Xavier Leleu, et al.
Journal of General Internal Medicine|April 9, 2022
WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity ScalesManuel Rubio-Rivas, José María Mora-Luján, Francesc Formiga, et al.
Journal of Clinical Medicine|March 6, 2021
Gender-Based Differences by Age Range in Patients Hospitalized with COVID-19: A Spanish Observational Cohort StudyClaudia Josa-Laorden, Anxela Crestelo-Vieitez, María Del Mar García Andreu, et al.
Blood|March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trialPhilippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I TrialXavier Leleu, Guillemette Fouquet, Valentine Richez, et al.
Annals of Medicine|October 16, 2020
Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 RegistryFrancisco Javier Carrasco-Sánchez, Mª Dolores López-Carmona, Francisco Javier Martínez-Marcos, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
Pageof 57

Showing results (551-560 of 568) with videos related to

Sort By:
Pageof 57
Plos One|February 19, 2021
Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 RegistryJesús Díez-Manglano, Marta Nataya Solís-Marquínez, Andrea Álvarez García, et al.
Haematologica|September 2, 2018
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphomaRémy Gressin, Nicolas Daguindau, Adrian Tempescul, et al.
Plos One|May 11, 2021
Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVIDJorge Calderón-Parra, Antonio Muiño-Miguez, Alejandro D Bendala-Estrada, et al.
Blood|September 24, 2025
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Aurore Perrot, Xavier Leleu, et al.
Journal of General Internal Medicine|April 9, 2022
WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity ScalesManuel Rubio-Rivas, José María Mora-Luján, Francesc Formiga, et al.
Journal of Clinical Medicine|March 6, 2021
Gender-Based Differences by Age Range in Patients Hospitalized with COVID-19: A Spanish Observational Cohort StudyClaudia Josa-Laorden, Anxela Crestelo-Vieitez, María Del Mar García Andreu, et al.
Blood|March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trialPhilippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I TrialXavier Leleu, Guillemette Fouquet, Valentine Richez, et al.
Annals of Medicine|October 16, 2020
Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 RegistryFrancisco Javier Carrasco-Sánchez, Mª Dolores López-Carmona, Francisco Javier Martínez-Marcos, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
Pageof 57